INFORMATION:
For more information contact:
Charli Scouller
PR Manager (School of Medicine and Dentistry)
Queen Mary University of London
c.scouller@qmul.ac.uk
Tel: 020 7882 7943
Notes to the editor
Full copies of the paper are available upon request.
About Queen Mary University of London
Queen Mary University of London is among the UK's leading research-intensive higher education institutions, with five campuses in the capital: Mile End, Whitechapel, Charterhouse Square, West Smithfield and Lincoln's Inn Fields.
A member of the Russell Group, Queen Mary is also one of the largest of the colleges of the University of London, with 17,800 students - 20 per cent of whom are from more than 150 countries.
Some 4,000 staff deliver world-class degrees and research across 21 departments, within three Faculties: Science and Engineering; Humanities and Social Sciences; and the School of Medicine and Dentistry.
Queen Mary has an annual turnover of £350m, research income worth £100m, and generates employment and output worth £700m to the UK economy each year.
Unique for London universities, Queen Mary has an integrated residential campus in Mile End - a 2,000-bed award-winning Student Village overlooking the scenic Regents Canal.
Scientists discover treatment breakthrough for advanced bladder cancer
2014-11-26
(Press-News.org) Scientists from Queen Mary University of London have made a breakthrough in developing a new therapy for advanced bladder cancer - for which there have been no major treatment advances in the past 30 years.
Published today in Nature, the study examined an antibody (MPDL3280A) which blocks a protein (PD-L1) thought to help cancer cells evade immune detection.
In a phase one, multi-centre international clinical trial, 68 patients with advanced bladder cancer (who had failed all other standard treatments such as chemotherapy) received MPDL3280A, a cancer immunotherapy medicine being developed by Roche. In addition, patients were all tested for the protein PD-L1 and around 30 were identified as having PD-L1 positive tumours.
After six weeks of treatment, 43 per cent of PD-L1-positive patients found their tumour had shrunk. This rose to 52 per cent after 12 weeks of follow up. In two of these patients (7 per cent) radiological imaging found no evidence of the cancer at all following the treatment. Among PD-L1 negative patients, 11 percent responded positively to treatment too.
Patients who had a positive response to treatment found the benefits were prolonged, and safety results were also encouraging, with fatigue and loss of appetite most commonly reported as side effects.
The early results of this trial are so promising, the MPDL3280A antibody drug has been given breakthrough therapy designation status by the U.S. FDA.
Dr Tom Powles, Lead Author and Consultant Medical Oncologist, Barts Cancer Institute, Queen Mary University of London, comments: "This study is a hugely exciting step forward in the search for alternative advanced bladder cancer treatment. For decades chemotherapy has been the only option, with a poor outcome and many patients too ill to cope with it. Not only has this investigational drug had a striking response rate, we can target this therapy for patients by screening specific protein PD-L1.
"We now need larger trials to confirm our findings, and as this drug has been given breakthrough designation status by the FDA, we hope to fast track this process so we can begin to give hope to the thousands of people affected by advanced bladder cancer each year."
Bladder cancer is the 7th most common cancer in the UK and around 10% of diagnoses are advanced (meaning the cancer has already spread to another part of the body). This makes it very difficult to treat, with chemotherapy the only option. On average patients live for 12 - 18 months following diagnosis, with many choosing to forgo chemotherapy due to its toxicity and limited survival benefit.
Also published in the same issue of Nature are broader results of this phase one study for the antibody MPDL3280A, with data from people with lung, kidney, colon or head & neck cancers authored by Roy Herbst, MD, PhD of the Yale Cancer Centre.
ELSE PRESS RELEASES FROM THIS DATE:
Shaping the future of energy storage with conductive clay
2014-11-26
In the race to find materials of ever increasing thinness, surface area and conductivity to make better performing battery electrodes, a lump of clay might have just taken the lead. Materials scientists from Drexel University's College of Engineering invented the clay, which is both highly conductive and can easily be molded into a variety of shapes and sizes. It represents a turn away from the rather complicated and costly processing--currently used to make materials for lithium-ion batteries and supercapacitors--and toward one that looks a bit like rolling out cookie ...
Star Trek-like invisible shield found thousands of miles above Earth
2014-11-26
A team led by the University of Colorado Boulder has discovered an invisible shield some 7,200 miles above Earth that blocks so-called "killer electrons," which whip around the planet at near-light speed and have been known to threaten astronauts, fry satellites and degrade space systems during intense solar storms.
The barrier to the particle motion was discovered in the Van Allen radiation belts, two doughnut-shaped rings above Earth that are filled with high-energy electrons and protons, said Distinguished Professor Daniel Baker, director of CU-Boulder's Laboratory ...
Vaccines may make war on cancer personal
2014-11-26
In the near future, physicians may treat some cancer patients with personalized vaccines that spur their immune systems to attack malignant tumors. New research led by scientists at Washington University School of Medicine in St. Louis has brought the approach one step closer to reality.
Like flu vaccines, cancer vaccines in development are designed to alert the immune system to be on the lookout for dangerous invaders. But instead of preparing the immune system for potential pathogen attacks, the vaccines will help key immune cells recognize the unique features of cancer ...
SU2C-supported research discovers why patients respond to a life-saving melanoma drug
2014-11-26
LOS ANGELES - November 26, 2014 - Work supported by the Stand Up To Cancer (SU2C) - Cancer Research Institute (CRI) - Immunology Translational Research Dream Team, launched in 2012 to focus on how the patient's own immune system can be harnessed to treat some cancers have pioneered an approach to predict why advanced melanoma patients respond to a new life-saving melanoma drug. This new drug, pembrolizumab (Keytruda), was recently approved by the FDA. These findings are reported in Nature online November 26, 2014, ahead of print in the journal.
Over a two-year study, ...
Researchers identify a natural shield against harmful radiation belt
2014-11-26
High above Earth's atmosphere, electrons whiz past at close to the speed of light. Such ultrarelativistic electrons, which make up the outer band of the Van Allen radiation belt, can streak around the planet in a mere five minutes, bombarding anything in their path. Exposure to such high-energy radiation can wreak havoc on satellite electronics, and pose serious health risks to astronauts.
Now researchers at MIT, the University of Colorado, and elsewhere have found there's a hard limit to how close ultrarelativistic electrons can get to the Earth. The team found that ...
Matched 'hybrid' systems may hold key to wider use of renewable energy
2014-11-26
CORVALLIS, Ore. - The use of renewable energy in the United States could take a significant leap forward with improved storage technologies or more efforts to "match" different forms of alternative energy systems that provide an overall more steady flow of electricity, researchers say in a new report.
Historically, a major drawback to the use and cost-effectiveness of alternative energy systems has been that they are too variable - if the wind doesn't blow or the sun doesn't shine, a completely different energy system has to be available to pick up the slack. This lack ...
NASA's Van Allen Probes spot an impenetrable barrier in space
2014-11-26
Two donuts of seething radiation that surround Earth, called the Van Allen radiation belts, have been found to contain a nearly impenetrable barrier that prevents the fastest, most energetic electrons from reaching Earth.
The Van Allen belts are a collection of charged particles, gathered in place by Earth's magnetic field. They can wax and wane in response to incoming energy from the sun, sometimes swelling up enough to expose satellites in low-Earth orbit to damaging radiation. The discovery of the drain that acts as a barrier within the belts was made using NASA's ...
Elderly brains learn, but maybe too much
2014-11-26
PROVIDENCE, R.I. [Brown University] -- A new study led by Brown University reports that older learners retained the mental flexibility needed to learn a visual perception task but were not as good as younger people at filtering out irrelevant information.
The findings undermine the conventional wisdom that the brains of older people lack flexibility, or "plasticity," but highlight a different reason why learning may become more difficult as people age: They learn more than they need to. Researchers call this the "plasticity and stability dilemma." The new study suggests ...
Dogs hear our words and how we say them
2014-11-26
VIDEO:
When people hear another person talking to them, they respond not only to what is being said -- those consonants and vowels strung together into words and sentences --but also...
Click here for more information.
When people hear another person talking to them, they respond not only to what is being said--those consonants and vowels strung together into words and sentences--but also to other features of that speech--the emotional tone and the speaker's gender, for instance. ...
With age, we lose our visual learning filter
2014-11-26
Older people can actually take in and learn from visual information more readily than younger people do, according to new evidence reported in the Cell Press journal Current Biology on November 26. This surprising discovery is explained by an apparent decline with age in the ability to filter out irrelevant information.
"It is quite counterintuitive that there is a case in which older individuals learn more than younger individuals," says Takeo Watanabe of Brown University.
Older individuals take in more at the same time as the stability of their visual perceptual ...